Metastatic Melanoma- Pipeline Insight, 2025

DelveInsight’s, “Metastatic Melanoma- Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metastatic Melanoma: Understanding

Metastatic Melanoma: Overview

Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. Metastatic melanoma is a disease that occurs when the cancerous cells from the original tumor (primary tumor) get loose, spread by traveling through the lymph or blood circulation, and start a new tumor (metastatic tumor) somewhere else. Once it spreads, or metastasizes, the disease is known as metastatic melanoma. This type of melanoma may typically occur during stage 3 or stage 4. Common melanoma metastasis sites include the lymph nodes, lungs, liver, bones and brain. Metastatic melanoma symptoms and signs may include: Fatigue, swollen or painful lymph nodes, weight loss, loss of appetite, trouble breathing or a cough that doesn’t go away, bone pain, headaches, seizures, swelling of the liver. Symptoms vary depending on where the metastasis spreads in the body. During diagnosing with melanoma, doctor will do a skin exam. If they think patient may have skin cancer, patient would need a biopsy to find out. Usually gets one of three types: Punch biopsy. This removes a round piece of skin. Excisional biopsy: doctor takes out the entire growth. Shave biopsy: doctor tries to shave off the entire growth. A doctor will look at the growth under a microscope to see how thick it is. Usually, a thicker tumor means there is a higher risk the cancer will spread. Additional tests are needed to determine whether the cancer is metastatic melanoma, or if there’s no visible primary tumor. To test for metastatic melanoma, or melanoma that has spread to lymph nodes or distant parts of the body, doctors may perform the following tests. Lymph node mapping and sentinel lymph node biopsy (SLNB), Computed tomography (CT) scan, positron emission tomography (PET) scan, magnetic resonance imaging (MRI) scan or ultrasound exam, Blood chemistry studies: Cancer may cause elevated or abnormal levels of certain substances in blood. A laboratory test can identify if blood chemistry shows signs of a cancerous tumor. Metastatic melanomas can be difficult to treat. The five-year survival rate for people diagnosed with melanoma that has spread to nearby lymph nodes is 66 percent, according to the American Cancer Society. When cancer has spread to distant parts of the body, there may also be other metastases too small to detect by scans. For people diagnosed with stage 4 melanoma, or melanoma that has spread to distant parts of the body, the five-year survival rate is 27 percent.

""Metastatic Melanoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Melanoma pipeline landscape is provided which includes the disease overview and Metastatic Melanoma treatment guidelines. The assessment part of the report embraces, in depth Metastatic Melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Melanoma.

Metastatic Melanoma Emerging Drugs Chapters

This segment of the Metastatic Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic Melanoma Emerging Drugs

• EVX 01: Evaxion Biotech

EVX-01, is a novel personalized cancer immunotherapy based on Evaxion’s proprietary PIONEER™ AI technology. EVX-01 is safe and has encouraging early indications of clinically and meaningful antitumor activity. Data showed EVX-01 is capable of eliciting T-cell responses in a clinical setting where the patients received concurrent standard immune therapy, i.e. anti-PD-1 treatment. Results demonstrated an antitumor effect in combination with anti-PD-1 treatment. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

• IN 10018: InxMed

IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

• AV MEL 1: AiVita Biomedical

AV MEL 1, is an investigational drug being developed by AiVita Biomedical. AIVITA has received IND approval to begin a Phase 1B trial investigating its cancer vaccine in patients with metastatic melanoma plus checkpoint inhibitors.

Further product details are provided in the report……..

Metastatic Melanoma: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic Melanoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Metastatic Melanoma

There are approx. 75+ key companies which are developing the therapies for Metastatic Melanoma. The companies which have their Metastatic Melanoma drug candidates in the most advanced stage, i.e. Phase II, Evaxion Biotech.

• Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Melanoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Melanoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Melanoma drugs.

Metastatic Melanoma Report Insights

• Metastatic Melanoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metastatic Melanoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metastatic Melanoma drugs?
• How many Metastatic Melanoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Melanoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Melanoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic Melanoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Evaxion Biotech
• InxMed
• AiVita Biomedical
• Iovance Biotherapeutics
• Viralytics
• Merck & Co.
• Neon Therapeutics
• BioNTech
• Bristol-Myers Squibb
• Ono Pharmaceuticals
• Cytovation AS

Key Products

• EVX 01
• IN 10018
• AV MEL 1
• Lifileucel
• V937
• NEO-PTC-01
• Relatlimab
• CyPep-1

Show more